Tuberculosis Control Program
BUMEDINST 6224.8
Chief, Bureau of Medicine and Surgery
February 8, 1993
Tuberculosis Screening Program
1. Screening on Entry into Naval Service
a. All personnel first entering duty in the regular Navy, the Naval Reserve, the Marine
Corps, and the Marine Corps Reserve for periods of duty in excess of 30 days, including
duty for training, and all persons beginning employment as CIVMARs for the Military
Sealift Command must have the result of a tuberculin skin test documented in their medical
treatment record.
b. Whenever possible, a person with a history of active disease, a history of a
previous reaction to a tuberculin skin test, or a history of INH
therapy must provide
adequate documentation of any prior tuberculin skin tests, clinical evaluations,
hospitalizations, diagnoses, and treatments. Adequate documentation includes copies of
pertinent medical records, immunization records, or a physician's statement on letterhead
stationary. Transcribe pertinent information into the medical treatment record. If such
documentation is not available, apply a 5 TU tuberculin skin test. Interpret and manage
any reaction per the guidelines of this instruction.
2. Periodic Screening. Screen personnel according to the following criteria:
a. Annual Screening. Required for personnel in operational units and in units with a
high risk for tuberculosis exposure or outbreaks, including:
(1) All shipboard personnel, both active duty and civil service.
(2) All members of deployable Navy and Marine Corps units, except for ready reservists.
(3) All health care workers, including medical and dental treatment facility workers
who are not members of the Medical Department.
(4) When recommended by the cognizant NAVENPVNTMEDU (e. g., certain high risk overseas
duty stations).
b. Triennial Screening. Required for all other personnel, such as those in low- risk
areas (e. g., active duty and Reserve shore- based personnel in the United States), at
least every 3 years. Appropriate times for required periodic testing include:
(1) Physical examinations.
(2) Receipt of permanent change of station (PCS) orders.
(3) Review of medical records by the Medical Department representative (MDR).
(4) Reporting for active duty for training (ACDUTRA).
3. Screening Before Separation From Naval Service. All personnel must have a
tuberculin skin test (or annual clinical evaluation in the case of a previously- known
(old) reactor) documented within the 1- year period before separation from the naval
service. 4. Radiograph Requirements
a. Entry into Naval Service. Obtain a chest radiograph only if clinically indicated for
the diagnosis or evaluation of suspected tuberculosis, or another medical condition, or if
required for programs with special physical qualifications. There is no requirement for a
chest radiograph as a routine part of the tuberculosis screening program for entry into
the naval service.
b. Separation From Naval Service. Obtain a chest radiograph only if clinically
indicated for the evaluation of tuberculosis or another medical condition or if required
for programs with special requirements. There is no requirement for a routine chest
radiograph as part of the separation physical examination.
c. Other Radiograph Requirements
(1) Chest radiographs are indicated for the following:
(a) All newly- identified tuberculin reactors as part of their evaluation to rule out
active disease.
(b) Any time active disease is suspected.
(c) Tuberculin reactors, including previously- known tuberculin reactors, who are
contacts of known, potentially-infectious cases of active disease.
(2) Chest radiographs are not indicated for the following:
(a) Previously- known tuberculin reactors (old reactors) as part of their required
annual evaluation, if they have remained asymptomatic.
(b) Tuberculin nonreactors.
5. Screening of Dependents. There is no routinely recommended program of
tuberculosis screening for dependents, except on the recommendation of the cognizant
NAVENPVNTMEDU for dependents living in areas at high risk for acquiring tuberculosis.
Screening of dependents who are contacts of a case of active disease is handled on a case-
by- case basis. This instruction does not preclude the routine screening of categories of
dependents when recommended by appropriate professional organizations, e. g., the American
Academy of Pediatrics. In general, tuberculosis screening of dependents follows the
procedures and techniques set out in this instruction.
6. Testing Procedures
a. Tuberculin Skin Test Materials
(1) Tuberculin, purified protein derivative (PPD). Per reference (a), the only approved
tuberculin skin test material for the routine Mantoux test is the premixed Tween- 80-
stabilized intermediate strength PPD (5 TU equivalent) available as NSN 6505- 00- 105-
0102 or NSN 6505- 00- 117- 8783.
(2) Other Tuberculin Preparations. Premixed Tween- 80- stabilized low strength PPD (1
TU equivalent), available as NSN 6505- 00- 117- 8784, is used for low- strength tuberculin
skin tests, when indicated.
(3) Multiple- puncture tuberculin tests (e. g., Tine or Monovac tests) produce
significant numbers of both false-positive and false- negative test results, and are not
to be used except on the specific recommendation of the area NAVENPVNTMEDU. The use of
multiple- puncture tuberculin tests in all children and adolescents shall be discontinued.
(4) Syringes and Needles. Use a disposable 1 ml tuberculin syringe graduated in 0.1 ml
intervals and fitted with a 25- gauge 5/ 8 inch needle, NSN 6515- 00- 982- 4205, for
administering the Mantoux test. Do not use the hypodermic jet injector for PPD
administration.
b. Tuberculin Skin Test Methods
(1) Personnel authorized to perform the tuberculin test. Only trained Medical
Department personnel can perform the tuberculin skin test. The senior MDR must verify in
writing that all personnel administering and interpreting the Mantoux test are trained and
competent.
(2) Techniques. The technique for the Mantoux method of tuberculin skin testing is
depicted in figure 1 and briefly described below.
(a) Prepare a tuberculin syringe with a single dose of 0.1 ml of intermediate strength
(5 TU) PPD. Fill the syringe immediately before use, because the solution can be absorbed
on the plastic of the syringe.
(b) Make an intradermal injection of 0.1 ml of intermediate strength (5 TU) PPD on the
volar aspect of the forearm. The injection site should be clean and dry.
(c) Check for evidence of a good intradermal injection. A properly applied skin test
will raise a small, pale, sharply demarcated wheal on the skin, which quickly disappears.
If no wheal appears, the PPD has been injected subcutaneously; immediately apply another
skin test on the opposite arm.
(d) Use the same method to apply a low strength (1 TU) test. Use 0.1 ml of low strength
(1 TU) PPD; do not attempt to dilute or use a reduced dose of 5 TU PPD.
(3) Measuring Results
(a) Examine the tuberculin skin test site 48 to 72 hours after administration. The test
must be read by an MDR who is both trained and experienced in reading and interpreting
tuberculin skin tests.
(b) Measure the induration (swelling) in millimeters at its widest transverse diameter
(across the arm). Redness without induration has no significance; ignore it.
(c) Measure and record any induration. SMALL REACTIONS (LESS THAN 10 MM) ARE IMPORTANT.
Measure and record them accurately.
(d) Keep the forearm relaxed and slightly flexed at the elbow. Find the margins of
induration by drawing the index or middle finger lightly across the reaction. Use a
flexible millimeter ruler to measure the transverse diameter of the induration. If the
measurement falls between two millimeter divisions of the scale, use the lower reading.
(e) If it is difficult to locate the margins, look at the reaction in a cross- light
while lightly drawing a finger over the reaction. If necessary, the extreme edges of
induration may be outlined by drawing onto the skin with a ballpoint pen. From 1 inch
beyond any palpable induration, apply the tip of the pen to the skin and draw a line
toward the induration. When a distinct change in rolling resistance is felt, remove the
pen tip from the skin. That is one edge of the induration. Repeat the steps on the
opposite side of the induration. Measure the distance in millimeters between the ends of
the two pen marks.
(4) Recording Results
(a) Enter the test technique and result in the medical treatment record. Record the
following information on SF 601 under SENSITIVITY TESTS: date, type of tuberculin and its
strength (e. g., PPD 5 TU), and the diameter of induration in millimeters. An example of
an entry is: "17 Sep 82 PPD (5 TU) 6 mm induration." Enter the information by
hand. Do not use rubber stamps or automatic imprinting devices.
(b) Any induration is important, and must be recorded according to its actual measured
size, e. g., "3 mm." Induration of less than 5 mm diameter must not be entered
as "nonsignifi- cant," "zero," or similar phrase. Enter the complete
absence of induration as "zero mm." Results must never be recorded as simply
"negative" or "positive."
c. Failure to Return for Test Interpretations
(1) If the person returns more than 72 hours after PPD application and the induration
is zero to 14 mm, make an entry of "not read" on the SF
601. Immediately apply a
PPD test on the opposite arm.
(2) If the person returns more than 72 hours, (but before or on the 10th day), after
PPD application and the induration is 15 mm or greater, the reaction is significant. Enter
the indura- tion and the time interval since test application on the SF
601. Manage the
person as a tuberculin reactor per enclosure (2). If there is uncertainty as to whether
the area of induration is 15 mm or greater, the test should be repeated as in the previous
paragraph.
(3) If the person returns more than 10 days after PPD application, make an entry of
"not read" on the SF 601 regardless of the size of any induration. Immediately
apply a PPD test on the opposite arm.
(4) If the person does not return at all, enter "not read" on the
SF 601.
Retest the person at the next opportunity.
(5) Do not under any circumstances report a skin test result as "zero mm" if
the test was not read by a qualified MDR.
d. Techniques for Screening Large Numbers of Individuals. Within a command, the best
opportunities for tuberculin skin are in the medical clinic or in sickbay during medical
check- in, during annual record and immunization review and update, and during visits for
other medical requirements. A tickler or recall system based on birth month is often
useful. Occasionally, a more aggressive program using the "house call" approach
may be necessary (e. g., large commands, contact investigations, or screening program
catch- up). A qualified MDR goes to the work-space (e. g., division quarters aboard ship)
to apply tuberculin skin tests. The MDR returns to the workspace in 48 to 72 hours to read
the test. The percentage of tests read may be higher with this method.
7. Significant Reactor Rate. During routine screening after the initial
(recruit/ officer accession) screening, the rate of newly-identified tuberculin reactors
normally is no more than 1 to 2 percent of personnel tested in most Navy and Marine Corps
set-tings. If the rate of newly- identified reactors is greater than 2.5 percent among any
group tested, consider searching for an active case of tuberculosis disease in the
command. Obtain specific guidance from the cognizant NAVENPVNTMEDU.
8. Special Situations
a. History of Bacillus Calmette- Guerin (BCG) Vaccination
(1) Ignore a person's BCG vaccine status when evaluating them for routine PPD
screening, contact investigation screening, or evaluation of suspected active clinical
tuberculosis.
(2) Many foreign countries use BCG vaccine for the prevention of tuberculosis,
especially among children. Most countries that use BCG vaccine have a significant risk of
tuberculosis infection in their population. While the vaccine may be effective in reducing
the risk of serious tuberculosis disease (e. g., meningitis) in childhood, its long- term
benefit is controversial. It is not used in the United States.
(3) Initially, BCG vaccine causes a reaction to the PPD skin test. The reaction is
usually less than 10 mm induration and disappears within 8 years of vaccination. There is
no reliable way to distinguish tuberculin reactions caused by BCG from those caused by
natural infection. A significant reaction to a 5 TU PPD skin test in a person with a
history of BCG vaccine usually means infection with M. tuberculosis. Such a person should
be managed per enclosure (2).
b. History of Tuberculosis Disease or Tuberculin Reaction. Persons with a history of
tuberculosis disease, a history of a previous reaction to intermediate strength PPD skin
test or a history of INH therapy must provide adequate documentation of their prior
evaluations, diagnoses and treatments whenever possible. Adequate documentation includes a
copy of pertinent medical records, a copy of immunization records, or a physician's
statement on letterhead stationery. If documentation is not available, follow the
guidelines of this instruction and document in the member's medical treatment record the
following: tuberculin skin test result, clinical evaluation (including chest x- ray, if
indicated), diagnosis, and appropriate preventive treatment.
c. Use of Low Strength PPD. When a person gives a history of a significant or severe
reaction to PPD, but has no documentation of such a reaction, repeat the tuberculin skin
test. The best method is to use intermediate strength (5 TU) PPD. This method is
standardized and the results are easier to interpret. However, if the person gives a
history of a large vesicular reaction, the health care provider may use low strength (1
TU) PPD, which may reduce but not eliminate the risk of another large reaction. A history
of a previous erythema nodosum reaction may also be an indication to use low strength PPD.
A reaction of 5 mm induration or greater to a 1 TU test is signifi-cant; handle the person
like a reactor with a 10 mm induration to a 5 TU test. If the reaction is less than 5 mm
induration, apply a 5 TU PPD immediately and read and interpret the test in the normal
manner.
d. Periodic Screening and the Booster Phenomenon
(1) Repeated or periodic testing of uninfected persons does not sensitize them to
tuberculin (PPD).
(2) A person develops a hypersensitivity to tuberculin protein after being infected
with M. tuberculosis or another mycobacteria (including BCG vaccine). (Hypersensitivity
does not develop from simple tuberculin skin testing, no matter how often a person
undergoes such testing.) The hypersensitivity, as measured by the amount of induration
produced by PPD testing, may gradually decrease over the years in some persons. These
persons may have no reaction, or only a small amount of induration, to tuberculin when
first tested many years (decades) after their initial infection. However, a tuberculin
skin test can stimulate or recall the hypersensitivity to its original degree of
indura-tion within several days. This effect does not appear in response to the skin test
which stimulated it, but produces an increased reaction (a "boosted" response)
on the next test. The booster phenomenon is most common in persons over age 55, but can
occur at any age.
(3) The booster phenomenon is a concern in a serial or periodic screening program,
because it may create the false impression of a new PPD conversion or a new infection. In
this situation, the first PPD skin test produces little or no induration, but the boosted
reaction, which occurs in response to a test routinely administered a year or more later,
is read as a positive skin test response. This positive response is then falsely
attributed to a tuberculosis infection newly acquired in the year between the first and
the subsequent test. In reality, this "positive" result is simply the boosted
response.
(a) Use an initial two- step testing procedure to reduce the likelihood of interpreting
a boosted response as evidence of a new infection. If the reaction to a first test is
classified as not significant as defined in table 1, apply a second test a week later. Use
the results of the second test as the baseline for subsequent testing. If the reaction to
the second test is significant, manage the person as infected. If the reaction to the
second test is not significant, manage the person as uninfected.
(b) The two- step procedure is most useful in older persons, such as older health care
workers entering an MTF screening program. Do not use the two- step procedure for recruit
or officer accession screening or other active duty screening programs.
|
|
Approved for public release;
Distribution is unlimited.
The listing of any non-Federal product in this CD is not an endorsement of the
product itself, but simply an acknowledgement of the source.
Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations
Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
*This web version is provided by
The Brookside Associates Medical Education Division. It contains
original contents from the official US Navy NAVMED P-5139, but has been
reformatted for web access and includes advertising and links that were not
present in the original version. This web version has not been approved by the
Department of the Navy or the Department of Defense. The presence of any
advertising on these pages does not constitute an endorsement of that product or
service by either the US Department of Defense or the Brookside Associates. The
Brookside Associates is a private organization, not affiliated with the United
States Department of Defense.
Contact Us · · Other
Brookside Products
|
Operational Medicine 2001
Contents
|
|